

## References

I-212

1. Hayes, Inc. Hayes Prognosis Overview. Spravato (Esketamine) for Treatment Resistant Depression. Landsdale, PA: Hayes, Inc.; March 2019.
2. Morrison R, Fedgchin m, Singh J, et al. Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Participants: a Randomized, Double-blind, Placebo-controlled Study. *Psychopharmacology*. 2018;235:1107-1119.
3. Daly E, Singh J, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression A Randomized Clinical Trial. *JAMA Psychiatry*. 2018;75(2):139-148.
4. Spravato™ (esketamine) nasal spray [package insert]. Titusville, NJ. Janssen Pharmaceuticals, Inc. 03/2019.
5. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
6. Canuso C, Singh J, Fedgchin M et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. *Am J Psychiatry*. 2018.;175:620-630.
7. Targum S, Daly E, Fedgchin M, Cooper K, & Singh J. Comparability of Blinded Remote and Site-Based Assessments of Response to Adjunctive Esketamine or Placebo Nasal Spray in Patients with Treatment Resistant Depression. *J Psych Res*. 2019;111:68-73.